Contrasting Tilray Brands (NASDAQ:TLRY) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Tilray Brands (NASDAQ:TLRY) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares Tilray Brands and Recordati Industria Chimica E Farmaceutica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-16.91%	-10.39%	-7.38%
Recordati Industria Chimica E Farmaceutica	18.38%	33.73%	12.76%

Analyst Ratings

This is a summary of current ratings and target prices for Tilray Brands and Recordati Industria Chimica E Farmaceutica, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2	2	3	1	2.38
Recordati Industria Chimica E Farmaceutica	0	1	0	1	3.00

Tilray Brands presently has a consensus price target of $5.90, indicating a potential upside of 94.08%. Given Tilray Brands’ higher probable upside, equities analysts plainly believe Tilray Brands is more favorable than Recordati Industria Chimica E Farmaceutica.

Valuation and Earnings

This table compares Tilray Brands and Recordati Industria Chimica E Farmaceutica”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$210.48 million	2.13	-$121.40 million	($1.40)	-2.17
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.10	$501.92 million	$2.80	21.00

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

9.4% of Tilray Brands shares are held by institutional investors. 1.6% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Tilray Brands has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Summary

Recordati Industria Chimica E Farmaceutica beats Tilray Brands on 9 of the 14 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.